January AI today announced the sale of its Eden’s synbiotic product line and related assets to ZBiotics, a leader in microbe innovation.
The acquisition brings together January AI’s pioneering prebiotic research with ZBiotics’ expertise in engineered probiotics, marking a new chapter in microbiome-based health solutions. Developed over six years with scientists from Stanford, the University of Michigan, and Tufts, Eden’s represented one of the most comprehensive prebiotic research programs ever conducted. Unlike conventional microbiome products centered on probiotics, Eden’s was built around prebiotics: fibers rationally selected through proprietary fermentation and biomarker assays to reshape microbiome function and drive measurable health outcomes.
The science was rigorous. Eden’s began with a vast universe of more than 28,000 known fibers, probiotics, and polyphenols. Through a literature review, in vitro screening, and functional experiments, the team narrowed down the list to 14 active ingredients with the most substantial impact.
In head-to-head testing, Eden’s fibers produced 4x more GLP-1, 3x more PYY, and nearly double the IL-10 compared to inulin and psyllium, two of today’s most widely used prebiotics.
Clinical studies demonstrated the benefits. After just one month of daily use, participants experienced:
Metabolic Health
● Lower fasting glucose in 91% of participants.
● 31% fewer glucose spikes in real-world meals during the “Rice Bowl Challenge.”
Microbiome Balance
● Expanded Bifidobacteria in 82% of participants.
● Boosted Ruminococcus bromii, a keystone starch degrader, in 83% of participants.
Immune & Inflammatory Response
● Improved cholesterol, raising cardioprotective HDL while reducing inflammatory cytokines more than fourfold.
● Higher levels of gut-brain metabolites (serotonin, GABA, and indole-3-propionic acid), supporting resilience, satiety, and reduced inflammation.
“Eden’s has been a part of my daily longevity routine for years, and I credit it with helping me feel resilient in my health,” said Noosheen Hashemi, Founder and CEO of January AI. “This sale ensures the science and community we built around Eden’s will continue to thrive under ZBiotics’ stewardship. I’ll always maintain a fiber habit, and I can’t wait to see how ZBiotics builds on Eden’s foundation.”
“January AI’s rigorous research and consumer impact with Eden’s aligns perfectly with our own focus on improving health and daily living with microbiology,” said Zack Abbott, PhD, co-founder and CEO of ZBiotics. “By combining their extensive synbiotic work with our expertise in synthetic biology, we see enormous potential to expand the ways microbiome innovation can improve people’s everyday lives.”
Eden’s has earned a loyal customer base that consistently reports gains in energy, satiety, and glycemic stability, proving that rigorous science can translate into tangible outcomes at scale.
With this transaction, January AI will sharpen its focus on its core mission: integrating AI, multiomic data, and nutrition intelligence to transform health outcomes for millions.
January AI is a precision health company using artificial intelligence to extend the world’s healthspan. Co-founded by Noosheen Hashemi, recently named to Forbes’ 50 Over 50 Women, and Dr. Michael Snyder of Stanford, the company began with a consumer app, now downloaded nearly 200,000 times, that predicts blood sugar responses to any food with a photo scan, barcode, voice, or search across a 54M+ food database. January AI is available to consumers as a mobile app and to healthcare organizations through an API. January AI has since expanded into enterprise solutions with Mirror, the first Health Context Engine built for safer, more competent healthcare. Recognized by CES, Fast Company, Inc., and The Wall Street Journal, January AI combines scientific depth with award-winning innovation to redefine how people, clinicians, and platforms use health data.
About ZBiotics
ZBiotics is a pioneering biotechnology company engineering probiotic bacteria to improve daily health and long-term wellness. Co-founded by scientist Zack Abbott, PhD, and Stephen Lamb, the company is best known for creating the world’s first genetically engineered probiotic—a patented innovation that redefined consumer accessibility to biotechnology. ZBiotics’ mission is to harness synthetic biology to solve everyday health challenges, bridging rigorous research with real-world impact. Trusted by hundreds of thousands of customers and featured by Fast Company, TIME, and The Wall Street Journal, ZBiotics combines cutting-edge science, transparency, and safety to lead the next generation of microbiome-based solutions.
Max Borges Agency
